American Society of Ketamine

Physicians, Psychotherapists & Practitioners

Who Is ASKP3?

The American Society of Ketamine Physicians, Psychotherapists, and Practitioners is a non-profit group of professionals dedicated to the safe clinical use of ketamine for mental health disorders and pain conditions.
0 +

Active members of ASKP3 worldwide.

0 +

Locations of our active members globally.

ASKP3 Upcoming Public Events

ASKP3 Past Public Events

ASKP3 Standards of Practice and Ethics Statement 2020

ASKP3 Mission Statement:

Our mission is to further awareness and education regarding safe, effective and ethical therapeutic use of ketamine

ASKP3 Vision Statement

Our vision is to advance the treatment of mental and physical health through the use of ketamine by:

2021-2022 ASKP3 Officers & Board Members

Sandhya Prashad, M.D.

Founding Member - President

Lisa Harding, MD

Board Member - Vice President

Erin Amato, MD

Board Member - Secretary

Steven Mandel, M.D.

Founding Member - Board Member

Patrick Sullivan, D.O.

Board Member

Nykol Bailey Rice, CRNA

Board Member

Jeffrey Becker, MD

Board Member

Rena Beyer, MSW, LCSW

Board Member

John Dougherty, DO

Board Member

Kathleen Barrett, PhD

Patient Advocate Board Member

Basics of Administration

The American Society of Ketamine Physicians, Psychotherapists, & Practitioners is a non-profit group of professionals dedicated to the safe clinical use of ketamine for mental health disorders and pain conditions.

ASKP3 serves as a forum to discuss the use of therapeutic ketamine for Non-Anesthetic Indications (KNAI). KNAI is fundamentally different than the traditional use of ketamine as an anesthetic.
We recognize that therapeutic ketamine is being administered by clinicians through different routes of delivery (IV, IM, IN, PO, etc.). ASKP3 does not endorse any particular route of delivery however we feel it is important that the combination of delivery and dose do not cross over from KNAI to moderate sedation unless the provider and clinical setting are appropriate for that treatment.
Patients should be screened for and have been found to have a condition that is appropriate for ketamine treatment – examples include Unipolar Major Depression, Bipolar Depression, PTSD, OCD, Fibromyalgia, CRPS and other forms of chronic pain.
A full history and physical including psychiatric disorders and substance abuse disorders should be completed in the patient’s chart. The patient’s medications and allergies should also be documented to reduce reasonable risk of medication interaction and side effects.
Given the off-label nature of ketamine use for these disorders, appropriate consent should be obtained.
Practitioners should have their established protocol easily available to the public. The use of “secret formulations” and “proprietary blends” runs counter to the concept of evidence-based medicine.
The patient’s vital signs should be monitored during administration and return to pre-administration values before discharge from the clinic.  An appropriately licensed and qualified medical provider should be present during the administration as well.
Patients receiving ketamine therapeutically should not be allowed to drive themselves home from their appointment, or for 12 hours after their infusion.
We do not support the use of medically unsupervised parenterally administered ketamine.

Stay up to date with ASKP3